Pulsed Violet Light Retinal Treatment for Non-Invasive Degeneration Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration and hereditary retinal degeneration, such as intravitreal injections, are invasive and associated with complications and side effects, while effective therapies are lacking for atrophic age-related macular degeneration and hereditary retinal degeneration.
Innovation Solution
Irradiating the subject with violet light of specific wavelengths (360-400 nm) continuously or in pulses at controlled frequencies to treat and prevent retinal degeneration, using a light irradiating apparatus with a controller to manage the light source.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravitreal injection of anti-VEGF antibody is used to treat exudative age-related macular degeneration, then treatment effectiveness is improved, but invasive treatment complications and side effects increase
Solution Approach 1:
The patent replaces the mechanical injection method with a non-invasive light irradiation method. Instead of injecting anti-VEGF antibodies into the vitreous body, the invention uses violet light (380-450 nm) to stimulate retinal cells and inhibit choroidal neovascularization through photobiological effects, thereby eliminating injection-related complications while maintaining treatment effectiveness
Solution Approach 2:
The patent changes the treatment parameter from chemical (anti-VEGF antibody) to physical (violet light wavelength 380-450 nm). By utilizing specific wavelength light to activate retinal photoreceptors and trigger biochemical pathways that inhibit neovascularization, the treatment achieves therapeutic effects without the harmful side effects associated with repeated injections
2Reliability
If repeated intravitreal injections are administered over a long period, then treatment effectiveness is maintained, but cumulative side effects and treatment burden increase
Solution Approach 1:
The patent employs periodic light irradiation sessions (e.g., 30 minutes per day, 5 days per week for 3 months) to achieve sustained therapeutic effects. This periodic stimulation of retinal photoreceptors with violet light maintains inhibition of choroidal neovascularization without requiring continuous or frequent interventions, thereby reducing treatment burden and time loss
3Ease of operation
If invasive treatment methods are used for atrophic age-related macular degeneration, then some symptomatic relief may be achieved, but no permanent cure is available and treatment options remain limited
Solution Approach 1:
The patent applies preliminary protective action by using violet light irradiation to prevent further photoreceptor cell death and geographic atrophy progression in atrophic AMD. By stimulating remaining retinal cells and promoting protective biochemical pathways before complete cell loss occurs, the treatment aims to preserve vision and potentially reverse early atrophic changes, offering hope for permanent improvement rather than temporary symptomatic relief
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a method for treating a retinal degeneration such as an age-related macular degeneration and a hereditary retinal degeneration by light stimulation in which light of a specific wavelength region such as violet light is pulsed at a specific frequency, and an apparatus used for the same. In the present invention, by irradiating a living body with light of a specific wavelength region such as violet light, at least one symptom selected from a group consisting of low vision, metamorphopsia, central scotoma, and complete loss of vision is improved or suppressed, and treatment and/or prophylaxis of the retinal degeneration such the age-related macular degeneration and the hereditary retinal degeneration is carried out.